Search Results - Pelaia G

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy by Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G

Connect to this object online.

Targeted therapy in severe asthma today: focus on immunoglobulin E by Pelaia G, Canonica GW, Matucci A, Paolini R, Triggiani M, Paggiaro P

Connect to this object online.

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies by Pelaia C, Vatrella A, Gallelli L, Lombardo N, Sciacqua A, Savino R, Pelaia G

Connect to this object online.

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab by Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G

Connect to this object online.

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD by Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Lombardo N, Maselli R

Connect to this object online.

Role of biologics in severe eosinophilic asthma – focus on reslizumab by Pelaia G, Vatrella A, Busceti MT, Gallelli L, Preianò M, Lombardo N, Terracciano R, Maselli R

Connect to this object online.

Theophylline action on primary human bronchial epithelial cells under proinflammatory stimuli and steroidal drugs: a therapeutic rationale approach by Gallelli L, Falcone D, Cannataro R, Perri M, Serra R, Pelaia G, Maselli R, Savino R, Spaziano G, D'Agostino B

Connect to this object online.